Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

SAN CARLOS, Calif., Dec. 27, 2023 -- Iovance Biotherapeutics, Inc. , a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte ...

Related Keywords

Sara Pellegrino ,Iovance Biotherapeutics ,Jen Saunders ,Friedrich Graf Finckenstein ,Drug Administration ,European Medicines Agency ,Nasdaq ,Investor Relations Corporate Communications ,Exchange Commission ,Globenewswire Inc ,National Cancer Database ,Iovance Biotherapeutics Inc ,Prescription Drug User Fee Act ,Graf Finckenstein ,Chief Medical Officer ,Cancer Database ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Medicines Agency ,Vice President ,Investor Relations ,Markets ,